Astion Pharma Strengthens Capital Base

The capital base of Astion Pharma A/S was recently increased by EUR 6,7 million to strengthen the company's development activities in the field of medical treatment of skin diseases. The fresh capital was provided by the existing shareholders.

Astion Pharma is experiencing very strong developments and has achieved significant and favourable results in several of the company's development projects. The company currently has three development projects in Phase II clinical studies for the treatment of hand dermatitis, seboroic dermatitis and cutaneous lupus in addition to a large portfolio of product candidates and research programmes in earlier phases.

For further information please contact:

Henrik Moltke,

CFO

Tel: +45 22 44 54 04

Email: hkm@astion.com

Or visit: www.astion.com